Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: Gut microbiota in liver cirrhosis and hepatocellular carcinoma

PROVIDER: PRJNA748675 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR15206981_1.fastq.gz	Fastqsanger.gz
	SRR15206981_2.fastq.gz	Fastqsanger.gz
	SRR15206982_1.fastq.gz	Fastqsanger.gz
	SRR15206982_2.fastq.gz	Fastqsanger.gz
	SRR15206983_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 6

Similar Datasets

E-GEOD-30485

Project description:Gene expression accompanying the promotion of hepatocellular carcinoma by intestinal microbiota and Tlr4 in mice.

2014-10-10 | E-GEOD-30485 | ExpressionAtlas

Quantitative proteome analysis of plasma microparticles for characterization of HCV-induced hepatic cirrhosis and hepatocellular carcinoma

Project description:A quantitative label-free proteome analysis was performed using plasma samples from 22 hepatitis-C virus (HCV)-induced liver cirrhosis patients, 16 HCV-positive hepatocellular carcinoma patients with underlying cirrhosis and 18 healthy controls. Plasma microparticles (PMPS) were isolated using ultracentrifugation and analyzed via label-free LC-MS/MS. A quantitative label-free proteome analysis was performed using plasma samples from 22 hepatitis-C virus (HCV)-induced liver cirrhosis patients, 16 HCV-positive hepatocellular carcinoma patients with underlying cirrhosis and 18 healthy controls. Plasma microparticles (PMPS) were isolated using ultracentrifugation and analyzed via label-free LC-MS/MS.

2020-03-12 | MSV000085094 | MassIVE

Quantitative proteome analysis of plasma microparticles for characterization of HCV-induced hepatic cirrhosis and hepatocellular carcinoma

2017-06-21 | PXD005777 | Pride

E-MTAB-8550

Project description:Gut microbiota and gallstone formation - cohousing study

2020-01-10 | E-MTAB-8550 | ExpressionAtlas

E-GEOD-60502

Project description:Gene expression profiling of 18 hepatocellular carcinoma and adjacent non-tumorous liver tissue

2025-01-24 | E-GEOD-60502 | ExpressionAtlas

Intact N-glycopeptides in Serum Haptoglobin between HCC and Cirrhosis

Project description:A workflow for differential analysis of the microheterogeneity of site-specific intact N-glycopeptides of serum haptoglobin between early hepatocellular carcinoma (HCC) and liver cirrhosis has been developed.

2018-10-25 | PXD011239 | Pride

Intestinal Mucosal Mitochondrial Oxidative Phosphorylation worsens with Cirrhosis Progression and is ameliorated with FMT

Project description:Intestinal barrier dysfunction, driven by increased oxidative phosphorylation (OXPHOS) activity that leads to tissue hypoxia, contributes to the progression of cirrhosis, particularly impacting the upper intestine. This study explores the interplay between intestinal OXPHOS, gut microbiota changes, and the effects of fecal microbiota transplant (FMT) in cirrhotic patients. We investigated 32 age-matched men across three groups: healthy controls, compensated cirrhosis, and decompensated cirrhosis. Each underwent endoscopy with duodenal and ascending colon biopsies. Subsequently, in a follow-up study, nine patients with hepatic encephalopathy, previously enrolled in a randomized controlled trial for FMT capsules, underwent repeat pre and post-FMT upper endoscopy. Our bioinformatics analysis highlighted a significant upregulation of nuclear-encoded OXPHOS genes in both intestinal regions of cirrhosis patients compared to controls, with further dysregulation in the decompensated group. We also observed a strong correlation between shifts in gut microbiota composition, Model for End-Stage Liver Disease (MELD) scores, and OXPHOS activity. Following FMT, patients displayed a significant reduction in OXPHOS gene expression in the duodenum, suggesting that FMT may restore intestinal barrier function and offer a therapeutic avenue to mitigate liver disease progression. The findings indicate that managing intestinal OXPHOS and microbiota through FMT could be relevant in modulating microbially-based therapies.

2024-12-26 | GSE285291 | GEO

EGFR inhibition prevents liver cirrhosis and hepatocellular carcinoma

Project description:EGFR inhibition prevents liver cirrhosis and hepatocellular carcinoma

| PRJNA138519 | ENA

Effect of endovascular treatment on gene expression in patients with Budd-Chiari syndrome

Project description:Budd-Chiari syndrome (BCS) results in sinusoidal congestion and hepatocyte apoptosis, which can further progress to liver fibrosis, cirrhosis, and hepatocellular carcinoma. Endovascular (EV) treatment has been the primary therapeutic method and achieved excellent outcomes. However, whether EV treatment could reverse liver cirrhosis in patients with BCS is still unclear. To investigate the effect of endovascular treatment on liver cirrhosis in patients with Budd-Chiari syndrome, we performed gene expression profiling analysis of the liver from patients with or without EV treatment.

2023-03-26 | GSE228205 | GEO

Project description:Gut microbiota in liver cirrhosis

| PRJNA1242070 | ENA